Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer And Prostatic Diseases 2013, 16: 266-270. PMID: 23712318, PMCID: PMC4026061, DOI: 10.1038/pcan.2013.15.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabChemotherapy, AdjuvantClinical Trials, Phase II as TopicDocetaxelHumansKallikreinsMagnetic Resonance ImagingMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalProspective StudiesProstatectomyProstate-Specific AntigenProstatic NeoplasmsTaxoidsTreatment OutcomeConceptsHigh-risk localized prostate cancerLocalized prostate cancerBiochemical recurrenceProstate cancerPSA responseNeoadjuvant chemotherapyLikelihood of biochemical recurrenceTreated with neoadjuvant docetaxelAssociated with inferior outcomesEndorectal magnetic resonance imagingResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapy trialsNeoadjuvant systemic therapyMedian Follow-UpMultivariate Cox regressionIntermediate end pointsMagnetic resonance imagingNeoadjuvant trialsNeoadjuvant docetaxelRadical prostatectomyPartial responseSystemic therapyChemotherapy trialsMinor responseErMRIParadoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).
Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Journal Of Clinical Oncology 2013, 31: 23-23. DOI: 10.1200/jco.2013.31.6_suppl.23.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerBiochemical recurrenceRadical prostatectomyPSA responseNeoadjuvant chemotherapyMedian time to biochemical recurrenceLikelihood of biochemical recurrenceTime to biochemical recurrenceAssociated with inferior outcomesResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapy trialsPerioperative systemic therapyLocalized prostate cancerMedian Follow-UpMultivariate Cox regressionEndorectal MRINeoadjuvant trialsNeoadjuvant docetaxelSystemic therapyChemotherapy trialsProstate cancerErMRIClinical parametersInferior outcomesProliferative tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply